Zusammenfassung
Die Bedingungen für eine optimale Akuttherapie des Myokardinfarkts sowie eine erfolgreiche Primär- und Sekundärprävention der KHK sind im deutschsprachigen Raum prinzipiell flächendeckend vorhanden. Im 11-jährigen Verlaufszeitraum des MONICA-Herzinfarktregisters Augsburg (1985 – 1995) konnte eine Abnahme der Herzinfarktinzidenz und -mortalität für Männer und postmenopausale Frauen um etwa 20% (p < 0,001) im Vergleich zur vorherigen Dekade verzeichnet werden. Mit Verkürzung der Prähospitalzeit und Einführung verbesserter therapeutischer Strategien wurden die Dauer des Krankenhausaufenthalts verkürzt und die 30 Tage-Letalität von 12 auf 8% gesenkt [22].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332: 80–85
Arnout J, Simoons M, DeBono D et al. (1992) Correlation between level of heparinization and patency of the infarct related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 20: 513–519
Arntz HR, Tebbe U, Schuster HP et al. (2000) Leitlinien zur Diagnostik and Therapie des akuten Herzinfarktes. Z Kardiol 89: 364–374
Brener SJ, Barr LA, Burchenal JE et al. for ReoPro and Primary PTCA Organisation and Randomized Trial (RAPPORT) Investigators (1997) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Lancet 349: 1422–1428
Cannon PC, Weintraub WS, Demopoulus LA et al. for the TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IITa inhibitor tirofiban. N Engl J Med 344: 1879–1887
CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329–1339
Chadda K, Goldstein S, Byington R, Curb JD (1986) Effect of propanolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73: 503–510
CIBIS II Investigators group (1999) The cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 353: 9–13
Dargie H, Colucci W, Ford I et al. for the CAPRICORN Investigators (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357: 1385–1390
FRISC II Investigators Group (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Lancet 354: 708–715
Gawaz MP (1999) Das Blutplättchen. Thieme, Stuttgart New York, pp 89–101
GISSI 1 Collaborative Group (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1: 397–402
Granger CG, Califf RM (1995) Stabilizing the unstable artery. In: Califf RM et al. (eds) Acute coronary care, 2nd ed Mosby-Year Book, St Louis, pp 525–541
Grobecker HF, Krämer BK (1996) Beta-Rezeptoren-Antagonisten. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 38–39
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico: GISSI 3 (1994) Effect of lisinopril and transdermal glyceryl trinitrat singly and together on a 6-week mortality and ventricular function after myocardial function. Lancet 343: 1115–1122
GUSTO II b Angioplasty Substudy Investigators (1997) A clinical trial comparison primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes. N Engl J Med 336: 1621–1628
Heinrath KM, Werdan K (1999) Medikamentöse Therapie mit ß-Blocken. In: Griebenow R, Gülker H, Dominiak P et al. (Hrsg) Autonomes Nervensystem and koronare Herzerkrankung. Novartis Pharma, Nürnberg, S 237–294
ISIS 1 (First International Study of Infarct Survival) Collaborative Group (1986) Randomised trial of intravenous atenolol among 16077 cases of suspected acute myocardial infarction. Lancet 2: 57–66
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 18187 cases of suspected acute myocardial infarction. Lancet 2: 349–360
ISIS-4 collaborative group (1991) Fourth international study of infarction survival: protocol for a large simple study of effect of oral mononitrate, of oral captopril, and of intravenous magnesium. Am J Cardiol 68: 87D - 100D
Louis A, Cleland JG, Crabbe Set al. (2001) Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientic Sessions of the ACC 2001. Eur J Heart Fail 3: 381–387
Löwel H, Engel S, Hörmann A et al. (2000) Akuter Myokardinfarkt aus epidemiologischer Sicht. In: Arntz HR, Schuster HP (Hrsg) Die Notfalltherapie bei akutem Myokardinfarkt. Steinkopff, Darmstadt, S 13–23
MERIT-HF Investigators Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001–2007
Mitka M (2001) Results of CURE trial for acute coronary syndrome. JAMA 285: 1828–1829
Montalescot G, Barragan P, Wittenberg O et al. for the Admiral Investigators (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895–1903
Neumann FJ, Blasini R, Schmitt C et al. (1998) Effect of glycoprotein IIb/IIIa blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98: 2695–2701
Packer M, Coats AJS, Fowler MB et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658
Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669–677
Roux S, Christeller S, Lüdin E (1992) Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a metaanalysis. J Am Coll Cardiol 19: 671–677
Ryan TJ, Antman EM, Brooks NH et al. (1990) ACC/AHA guidelines for the management of patient with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 31: 1016–1030
Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 334: 1383–1389
Schömig A, Kastrati A, Dirschinger J et al. for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patient with Acute Myokardial Infarction Study Investigators (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343: 385–391
Schwartz L, Bourassa MG, Lesperance J et al. (1988) Aspirin and dipyridamol in the prevention of restenosis after PTCA. N Engl J Med 318: 1714–1719
Statistisches Bundesamt Gesundheitswesen (1999) Fachserie 12, Reihe 4 Todesursachen 1997. Statistisches Bundesamt, Wiesbaden
Swedberg K, Held P, Kjekshus J et al. (1992) Effect of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327: 678–684
The Acute Infarction Ramipril Efficacy Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828
The GUSTO I Investigators (1993) An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682
TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. Eur Heart J 6: 618–627
Topol EJ, Califf RM, Van de Werf F et al. for the GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357: 1905–1914
Weaver WD, Simes RJ, Betriu A et al. (1997) Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 278: 2093–2098
Weis, AC, Gulba DC (1999) Thrombolysetherapie des akuten Myokardinfarktes and adjuvante Therapien. In: Griebenow R, Gülker H, Dominiak P et al. (Hrsg.) Autonomes Nervensystem and koronare Herzerkrankung. Novartis Pharma, Nürnberg, S 138–150
Witthaut R, Werdan K (1998) Neue Aspekte der Therapie des akuten Myokardinfarktes für den Notarzt. Intensiv-Notfallbehandlung 23: 107–118
Yusuf S, Peto R, Lewis Jet al. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371
Yusuf S, Wittes J, Friedman J (1988) Overview of results of randomized clinical trials in heart disease. Treatments following myocardial infarction. JAMA 260: 2088–2093
Zijlstra F, Hoorntje JC, de Boer MJ et al. (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341: 1413–1419
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Steinkopff Verlag Darmstadt
About this chapter
Cite this chapter
Schneider, H., Weber, F., Nienaber, C. (2001). Akuter Herzinfarkt im Zeitalter von Lyse und Akut-PTCA: Hat sich die Bedeutung der β-Blocker-Therapie geändert?. In: Rauch, B., Held, K. (eds) Der schwerkranke und multimorbide Herzpatient. Steinkopff. https://doi.org/10.1007/978-3-642-93723-1_21
Download citation
DOI: https://doi.org/10.1007/978-3-642-93723-1_21
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-1323-5
Online ISBN: 978-3-642-93723-1
eBook Packages: Springer Book Archive